A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR

Trial Profile

A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin
  • Indications Peripheral arterial disorders
  • Focus Therapeutic Use
  • Acronyms TI-PAD EVR
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 08 Apr 2016 Planned End Date changed from 1 Mar 2017 to 1 May 2016, as reported by ClinicalTrials.gov.
    • 08 Apr 2016 Planned primary completion date changed from 1 Mar 2017 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top